RYE, N.Y., July 17, 2012 /PRNewswire/ -- Curemark today announced the appointment of Matthew F. Heil, PhD, to the position of Chief Scientific Officer. Currently, Dr. Heil is serving as Curemark's Senior Vice President for Research and Product Development.
Additionally, Curemark announced the appointment of James Szigethy, R. Ph. to the position of Vice President of Research and Product Development from Director of Research and Product Development.
Dr. Joan Fallon, Curemark Founder and CEO, announced the promotions and stated, "Dr. Heil's contributions and strategic insight into our product pipeline as well as our Phase III trial for CM-AT in autism have been invaluable. As we maximize the value of our products and platform, Dr. Heil is the perfect person to lead the charge. He is an accomplished scientist and wonderful collaborator."
Dr. Heil commented, "Working on the development of Curemark's autism product has been the highlight of my professional career. Leading Curemark's scientific team is a very exciting opportunity and I'm thrilled that I will be able to work closely with James Szigethy in his new capacity as we move to optimize our product pipeline."
Dr. Heil has more than two decades of experience in the pharmaceutical and biotechnology industries, and has served on multiple corporate boards. His successful areas of work include product development, regulatory affairs, strategic partnering and epidemiologic analysis. Dr. Heil received his PhD from Syracuse University in Immunology and has been a faculty member of the New York College of Medicine, as well as co-director of its clinical immunology-testing laboratory.
James Szigethy is a graduate of Rutgers University College of Pharmacy and received his BA in Psychology from St. John's University in Queens, New York.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company announced in December, 2011, that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark LLC